Roche Holding, CH1499059983

Roche Holding stock: Wilserdly wins FDA approval in breast cancer

Published on 11/18/2026 at 18:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding stock gains a new oncology milestone as the FDA clears Wilserdly with everolimus for a defined advanced breast cancer setting. A further US decision could broaden its use.

Roche expands its oncology pipeline

  • The FDA approved Wilserdly with everolimus for adults with a defined form of advanced or metastatic breast cancer.
  • An additional FDA decision could extend the treatment into earlier-stage disease.
  • The oral regimen targets endocrine-treatment resistance and may broaden Roche's oncology commercial opportunity.
Roche Holding, CH1499059983, Illustration mit AI erstellt.

Roche has secured US regulatory approval for Wilserdly in combination with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The decision was announced by Roche on Monday, November 16, 2026, and was reported by PharmaBiz.

Approval targets treatment resistance

The approval covers patients whose disease has returned during or after endocrine-based adjuvant therapy, or progressed after at least one endocrine-based regimen in the metastatic setting. The treatment combines the oral selective estrogen receptor degrader giredestrant with everolimus, an approach aimed at blocking separate signaling routes involved in treatment resistance.

The decision was supported by the phase III evERA Breast Cancer study. In patients with ESR1-mutated disease previously treated with a CDK4/6 inhibitor and endocrine therapy, Wilserdly plus everolimus reduced the risk of disease progression or death by 62 percent compared with standard endocrine therapy plus everolimus.

Next FDA decision due November 30

Roche has also filed Wilserdly for adults with ER-positive, HER2-negative stage I, II and III breast cancer at intermediate to high risk of recurrence. The FDA accepted that application for Priority Review and set a Prescription Drug User Fee Act date of November 30, 2026. A positive decision would move the medicine into an earlier treatment setting and potentially broaden its patient population.

Roche Holding stock traded at 436.55 euros on Lang & Schwarz at 18:00 CET on Wednesday, November 18, 2026.

Roche Holding at a glance

  • Company: Roche Holding AG
  • ISIN: CH1499059983
  • Exchange: SIX Swiss Exchange
  • Lang & Schwarz price: 436.55 euros on Wednesday, November 18, 2026, at 18:00 CET
  • Regulatory event: US FDA approval of Wilserdly with everolimus announced on November 16, 2026

Current market reports are available in the market reports.

More news and analyses on Roche Holding stock.

Disclaimer...
en | CH1499059983 | ROCHE HOLDING | boerse | 70531966 | bgmi